Overview

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-11-08
Target enrollment:
Participant gender:
Summary
This study will assess the pharmacokinetics (PK), safety, and tolerability of CAB ULA administered every 4 months (Q4M) following administration of CAB LA every 2 months (Q2M), in healthy adult volunteers.
Phase:
PHASE1
Details
Lead Sponsor:
ViiV Healthcare